European Journal of Clinical Pharmacology

, Volume 17, Issue 5, pp 321–328 | Cite as

Time course of blood pressure, pulse rate, plasma renin and metoprolol during treatment of hypertensive patients

  • K. Haglund
  • P. Collste
Originals

Summary

Eleven patients were treated for essential hypertension with metoprolol (Selokén®) for more than three months. The time course of changes in blood pressure, pulse rate and plasma renin activity was studied during treatment with an oral maintenance dose of 100 mg twice daily. Significant decreases in pulse rate, diastolic blood pressure and plasma renin activity were observed even after the first dose. The plasma concentration of metoprolol reached equilibrium after the second dose. After the third dose there was no further significant change in blood pressure. There was a significant correlation (p<0.001) between the initial (after three doses) and final (after >90days) effect of metoprolol on blood pressure (r=0.86 and 0.91 for systolic and diastolic blood pressure change, respectively).

Key words

metoprolol hypertension pharmacokinetics plasma renin blood pressure effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Åblad B, Borg KO, Carlsson E, Johnsson G, Malmfors T, Regårdh C-G (1975) Animal and human pharmacological studies on metoprolol — a new selective adrenergic beta1-receptor antagonist. Acta Pharmacol Toxicol 36 (Suppl 5)Google Scholar
  2. Alhenc-Gelas F, Plouin P-F, Ducrocq M-B, Corvol P, Menard J (1978) Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. Am J Med 64: 1005Google Scholar
  3. Anavekar SN, Louis WJ, Morgan TO, Doyle AE, Johnston CI (1975) The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels Clin Exp Pharmacol Physiol 2: 203Google Scholar
  4. von Bahr C, Collste P, Frisk-Holmberg M, Haglund K, Jorfelt L, Orme M, Östman J, Sjöqvist F (1976) Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension. Clin Pharmacol Ther 20: 130Google Scholar
  5. Bayliss PFC, Duncan SM (1975) The effects of atenolol (Tenormin) and metyldopa on simple tests of central nervous function. Br J Clin Pharmacol 2: 527Google Scholar
  6. Bengtsson C (1976) The effect of metoprolol — a new selective adrenergic beta1-receptor blocking agent — in mild hypertension. Acta Med Scand 199: 65Google Scholar
  7. Bravo EL, Tarazi RC, Dustan HP (1975) Beta-adrenergic blockade in diuretic-treated patients with essential hypertension. N Engl J Med 292: 66Google Scholar
  8. Brunner L, Imhof P, Jack D (1975) Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man. Eur J Clin Pharmacol 8: 3Google Scholar
  9. Bühler FR, Burkart F, Lütold BE, Küng M, Marbet G, Pfisterer M (1975) Antihypertensive beta blocking action as related to renin and age: A pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 36: 653Google Scholar
  10. Chidsey C, Pine M, Favrot L, Smith S, Leonetti G, Morselli P, Zanchetti A (1976) The use of drug concentration measurements in studies of the therapeutic response to propranolol. Postgrad Med J 52 (Suppl 4): 26Google Scholar
  11. Collste P (1978) The pharmacokinetics of alprenolol and metoprolol in relation to beta-adrenoceptor blockade and antihypertensive effect. MD Thesis, Karolinska Institutet, StockholmGoogle Scholar
  12. Collste P, Haglund K, von Bahr C (1980) Plasma levels and effects of metoprolol after single and multiple oral doses. Clin Pharmacol Ther (in press)Google Scholar
  13. Comerford MB, Pringle A (1976) Metoprolol in the long-term treatment of hypertension. Practitioner 217:953Google Scholar
  14. Ervik M (1975) Quantitative determination of metoprolol in plasma and urine by gas chromatography. Acta Pharmacol Toxicol 36 (Suppl 5): 136Google Scholar
  15. Fagard R, Amery A, dePlaen J-F, Lijnen P, Missotten A (1976) Relative value of beta blockers and thiazides for initiating antihypertensive therapy. Acta Cardiol 31: 411Google Scholar
  16. George CF, Lewis PJ, Petrie A (1975) Clinical experience with use of ultrasound sphygmomanometer. Br Heart J 37: 804Google Scholar
  17. Hansson L, Zweifler AJ (1974) The effect of propranolol on plasma renin activity and blood pressure in mild essential hypertension. Acta Med Scand 195: 397Google Scholar
  18. Lewis PJ, Haeusler G (1975) Reduction in sympathetic nervous activity as a mechanism for hypotensive effect of propranolol. Nature 256: 446Google Scholar
  19. Ljung B, Åblad B, Drews L, Fellenius A, Kjellstedt A, Wallborg M (1976) Anti-hypertensive effect of metoprolol in spontaneously hypertensive rats. Clin Sci Mol Med 51: 443Google Scholar
  20. Lund-Johansen P, Ohm OJ (1977) Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension. Br J Clin Pharmacol 4: 147Google Scholar
  21. Morgan TO, Roberts R, Carney SL, Louis WJ, Doyle AE (1975) Beta-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol 2: 159Google Scholar
  22. Muiesan G, Motolese M, Colombi A (1973) Hypotensive effect of oxprenolol in mild hypertension. A co-operative controlled study. Clin Sci Mol Med 45: 163Google Scholar
  23. Pedersen OL (1976) Comparison of metoprolol and hydrochlorthiazide as antihypertensive agents. Eur J Clin Pharmacol 10: 381Google Scholar
  24. Prichard BNC, Gillam PMS (1964) Use of propranolol (Inderal) in treatment of hypertension. Br Med J 2: 725Google Scholar
  25. Raine AEG, Churbb IW (1977) Long term beta-adrenergic blockade reduces tyrosine hydroxylase and dopamine beta-hydroxylase activities in sympathetic ganglia. Nature 267: 265Google Scholar
  26. Sannerstedt R (1975) Haemodynamic effects of adrenergic beta-receptor-blocking agents in arterial hypertension. In: Berglund G, Hansson L, Werkö L (eds). Pathophysiology and management of arterial hypertension. Lindgren, Mölndal, pp 194–200Google Scholar
  27. Sealey JE, Laragh JH (1973) Searching out low renin patients: Limitations of some commonly used methods. Am J Med 55: 303Google Scholar
  28. Snedecor GW, Cochran WC (1967) Statistical methods. 6th ed. Iowa State University Press, Ames, IowaGoogle Scholar
  29. Stokes GS, Weber MA, Thornell IR, Stoker LM, Sebel EF (1974) Effects of acute and chronic administration of propranolol on blood pressure and plasma renin activity in hypertensive patients. Prog Biochem Pharmacol 9: 29Google Scholar
  30. Stumpe KO, Kolloch R, Vetter H, Gramann W, Krück F, Ressel Ch, Higuchi M (1976) Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure. Am J Med 60: 853Google Scholar
  31. Tewari SN (1968) Propranolol in hypertension. Br Med J 3: 313Google Scholar
  32. Waal HJ (1966) Hypotensive action of propranolol. Clin Pharmacol Ther 7: 588Google Scholar
  33. Weiss YA, Loria Y, Safar ME, Lavene DE, Simon ACh, Georges DR, Milliez PL (1977) Relationship between the antihypertensive effect and the drug plasma concentration of pindolol. Curr Ther Res 21: 644Google Scholar
  34. Zanchetti A, Stella A, Leonetti G, Morganti A, Terzoli L (1976) Control of renin release. A review of experimental evidence and clinical implications. Am J Cardiol 37: 675Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • K. Haglund
    • 1
  • P. Collste
    • 1
  1. 1.Departments of Internal Medicine and Clinical Pharmacology, Karolinska InstitutetHuddinge University HospitalHuddingeSweden

Personalised recommendations